Immucell earnings were -$2.2M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest ICCC earnings report on Dec 31, 2024 announced Q4 2024 earnings of $514.6k, down 173.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ICCC reported annual earnings of -$2.2M, with -62.7% growth. The next ICCC earnings date is Jun 13, 2025.
On ICCC's earnings call on Invalid Date, Immucell (NASDAQ: ICCC) reported Q4 2024 earnings per share (EPS) of $0.08, up 153.33% year over year. Total ICCC earnings for the quarter were $514.56 thousand. In the same quarter last year, Immucell's earnings per share (EPS) was -$0.15.
The next ICCC earnings date is Invalid Date. Add ICCC to your watchlist to be reminded of Immucell's next earnings date.
What was ICCC's earnings growth in the past year?
As of Immucell's earnings date in Invalid Date, Immucell's earnings has grown year over year. ICCC earnings in the past year totalled -$2.16 million.
Is Immucell profitable or losing money?
As of the last Immucell earnings report, Immucell is currently losing money. Immucell's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$2.16 million, a 62.65% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.